Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.

Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.

Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y.

Cancer Sci. 2009 Jan;100(1):54-61. doi: 10.1111/j.1349-7006.2008.01005.x. Epub 2008 Nov 25.

2.

Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.

Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.

Br J Dermatol. 2005 Jul;153(1):167-73. Review.

PMID:
16029344
3.

The therapeutic use of rituximab in non-Hodgkin's lymphoma.

Marcus R, Hagenbeek A.

Eur J Haematol Suppl. 2007 Jan;(67):5-14. Review.

PMID:
17206982
4.

Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?

Clavio M, Quintino S, Venturino C, Ballerini F, Varaldo R, Gatto S, Galbusera V, Garrone A, Grasso R, Canepa L, Miglino M, Pierri I, Gobbi M.

J Exp Clin Cancer Res. 2001 Sep;20(3):351-8. Review.

PMID:
11718214
6.

Rituximab therapy for indolent non-Hodgkin's lymphoma.

Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M.

Anticancer Drugs. 2002 Nov;13 Suppl 2:S11-7. Review.

PMID:
12710586
7.

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.

Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clò V, Casolari B.

Crit Rev Oncol Hematol. 2001 Jan;37(1):13-25. Review.

PMID:
11164715
8.

The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.

Zhou X, Hu W, Qin X.

Oncologist. 2008 Sep;13(9):954-66. doi: 10.1634/theoncologist.2008-0089. Epub 2008 Sep 8. Review.

9.

[Rituximab].

Okamoto R, Maeda Y, Sasaki T.

Gan To Kagaku Ryoho. 2003 Aug;30(8):1085-93. Review. Japanese.

PMID:
12938262
10.

Rituximab for the treatment of diffuse large B-cell lymphomas.

Held G, Pöschel V, Pfreundschuh M.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1175-86. Review.

PMID:
16925484
11.

Antibodies for the treatment of diffuse large cell lymphoma.

Blum KA, Bartlett NL.

Semin Oncol. 2003 Aug;30(4):448-56. Review.

PMID:
12939713
12.

Rituximab: an innovative therapy for non-Hodgkin's lymphoma.

Wood AM.

Am J Health Syst Pharm. 2001 Feb 1;58(3):215-29; quiz 230-2. Review.

PMID:
11217177
13.

Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.

Bonavida B, Vega MI.

Drug Resist Updat. 2005 Feb-Apr;8(1-2):27-41. Epub 2005 Apr 8. Review.

PMID:
15939340
14.

[Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].

Tobinai K.

Gan To Kagaku Ryoho. 2002 Mar;29(3):473-80. Review. Japanese.

PMID:
11915743
15.

Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.

Collins-Burow B, Santos ES.

Expert Rev Anticancer Ther. 2007 Mar;7(3):257-73. Review.

PMID:
17338647
16.

Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.

Griffin MM, Morley N.

Expert Opin Biol Ther. 2013 May;13(5):803-11. doi: 10.1517/14712598.2013.786698. Review.

PMID:
23560506
17.

Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.

Bosly A, Keating MJ, Stasi R, Bradstock K.

Anticancer Drugs. 2002 Nov;13 Suppl 2:S25-33. Review.

PMID:
12710588
18.

Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.

King KM, Younes A.

Expert Rev Anticancer Ther. 2001 Aug;1(2):177-86. Review.

PMID:
12113023
19.
20.

[Rituximab in the treatment of B-cell non-Hodgkin lymphoma].

Mitrović Z, Aurer I.

Lijec Vjesn. 2006 Jan-Feb;128(1-2):36-42. Review. Croatian.

PMID:
16640226

Supplemental Content

Support Center